Crimson Publishers Publish With Us Reprints e-Books Video articles


Advances in Complementary & Alternative medicine

Gut Microbiome and Mechanisms of Primary and Acquired Resistance To PD-1/PD-L1 Blockade

  • Open or CloseShiyun Cui1, Ruihan Zou2 and Yongqian Shu1*

    1Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, China

    2The First School of Clinical Medicine, Nanjing Medical University, China

    *Corresponding author: Yongqian Shu, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu, China

Submission: August 19, 2021; Published: September 21, 2021

DOI: 10.31031/ACAM.2021.06.000645

ISSN: 2637-7802
Volume6 Issue4


PD-1/PD-L1 blockade is a promising immunotherapy, which provides a new method for the treatment of a variety of tumors and has significant clinical efficacy. However, most patients are not initially sensitive to these therapies, known as primary resistance. Unfortunately, some patients develop acquired resistance even after an initial response to PD-1/PD-L1 blockade. In fact, the mechanisms of primary and acquired resistance are not fully and clearly understood. Recently, the role of gut microbiome has also become a hot topic of research. From the above aspects, this article will discuss the related mechanisms and new strategies to improve the curative effect.

Keywords: Immune checkpoint blockade therapy; Immunotherapy resistance; Microbiome

Get access to the full text of this article